E 06
Alternative Names: E-06; S2G6T-1Latest Information Update: 02 Dec 2020
At a glance
- Originator Sol-Gel Technologies
- Class Antifungals; Steroids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Tinea pedis
Most Recent Events
- 18 Nov 2020 Sol-Gel Technologies discontinues a phase II trial in Tinea pedis in USA (Topical) as it failed to meet success criteria (NCT02842021)
- 01 Sep 2016 Phase-II clinical trials in Tinea pedis in USA (Topical) (NCT02842021)
- 19 Jul 2016 Sol-Gel Technologies plans a phase II trial for Tinea pedis (In adolescents, In adults) in USA (Topical) (NCT02842021)